Logo

Exagen Raises $7M in Series B Private-Equity Round

Jun 28, 2005

NEW YORK, June 28 (GenomeWeb News) -  Exagen Diagnostics has raised $7 million in a Series B round of private-equity financing, the company said today. 

 

Tullis-Dickerson led the round, while vSpring Capital and Wasatch Venture Fund participated. As GenomeWeb News has reported, Exagen completed a $5.7 million Series A round in early 2004 with the same group of investors.

 

Exagen, based in Albuquerque, NM, uses computational methods to develop genomic markers. It is currently validating prognostic marker sets for breast cancer and hepatitis C that aim to guide treatment decisions.

 

The company said its first test will be the Key2 Breast Cancer Prognosis panel, which is designed to detect changes in DNA copy number in both hormone receptor-positive and hormone receptor-negative tumors.

Breaking News
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.